on ONWARD MEDICAL NV (isin : NL0015000HT4)
ONWARD Medical: 2024 Results and Progress to Start 2025
ONWARD Medical reported its 2024 financial results with notable progress. The company obtained FDA approval to market its ARC-EX system in the United States, generating its first sales through strategic partnerships. Ottobock invested in ONWARD, strengthening its financial visibility. The company expanded its technology portfolio by acquiring exclusive rights to a cutting-edge brain-machine interface.
Operating expenses increased slightly to €36.6 million, while the company recorded a net loss of €35.7 million for 2024. However, its net cash position doubled to €60 million. ONWARD is now focusing on commercial expansion and innovative clinical developments for 2025.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ONWARD MEDICAL NV news